Meanwhile, the expression of CD137 and CD107a in CD8+ T and NK cells were improved by combined administration of IL‐33 and cetuximab (Figure 4D–E), which was also consistent with the data from cetuximab‐treated patients with CRC. Here, IL33 is linked to colorectal carcinoma.